Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients

Blood Purification

Volumn 23, Issue 6, 2005, Pages 421-428

  Filippidis, Georgios ^a   Liakopoulos, Vasilios ^a   Mertens, Peter Rene ^b   Kiropoulos, Theodoros ^a   Stakias, Nikolaos ^a   Verikouki, Christina ^a   Patsidis, Eftichios ^a   Koukoulis, Georgios ^a   Stefanidis, Ioannis ^a,c  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Adiponectin; Hemodialysis; Homeostasis model; Insulin resistance; Obesity; Resistin; Uremia

Indexed keywords

ADIPONECTIN; GLUCOSE; INSULIN; RESISTIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CALCULATION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; ENZYME IMMUNOASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH STATUS; HEMOCONCENTRATION; HEMODIALYSIS; HOMEOSTASIS; HUMAN; IMMUNOASSAY; IMPEDANCE; INFECTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY FAILURE; MALE; PREVALENCE; PRIORITY JOURNAL; SERUM; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TIME; VOLUNTEER;

ADIPONECTIN; BODY MASS INDEX; FEMALE; HUMANS; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RESISTIN;

EID: 29144508512     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088017     Document Type: Article

References (39)

1. DeFronzo RA, Tobin JD, Rowe JW, Andres R: Glucose intolerance in uremia. Quantification of pancreatic β-cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 1978;62:425-435.
2. Mak RH, DeFronzo RA: Glucose and insulin metabolism in uremia. Nephron 1992;61:377-382.
3. Adrogue HJ: Glucose homeostasis and the kidney. Kidney Int 1992;42:1266-1282.
4. McCaleb ML, Izzo MS, Lockwood DH: Characterization and partial purification of a factor from uremic human serum that induces insulin resistance. J Clin Invest 1985;75:391-396.
5. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
6. Kim KH, Lee K, Moon YS, Sul HS: A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001;276:11252-11256.
7. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale FV Jr, Shelton DL, Hebert CC: FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000;19:4046-4055.
8. Diez JJ, Iglesias P: The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293-300.
9. 2) as a measure of fatness. Int J Obes 1985;9:147-153.
10. Katzarski K, Charra B, Laurent G, Lopot F, Divino-Filho JC, Nisell J, Bergstrom J: Multi-frequency bioimpedance in assessment of dry weight in haemodialysis. Nephrol Dial Transplant 1996;11(suppl 2):20-23.
11. t/V from an intradialytic sample: effects of access and cardiopulmonary recirculations. Kidney Int 1995;48:832-837.
12. Daugirdas JT, Burke MS, Balter P, Priester-Coary A, Majka T: Screening for extreme postdialysis urea rebound using the Smye method: patients with access recirculation identified when a slow flow method is not used to draw the postdialysis blood. Am J Kidney Dis 1996;28:727-731.
13. Van Beaumont W: Evaluation of hemoconcentration from hematocrit measurements. J Appl Physiol 1972;32:712-713.
14. Sargent J, Gotch F, Borah M, Piercy L, Spinozzi N, Schoenfeld P, Humphreys M: Urea kinetics: a guide to nutritional management of renal failure. Am J Clin Nutr 1978;31:1696-1702.
15. t/V: an analysis of error. J Am Soc Nephrol 1993;4:1205-1213.
16. Clark PM: Assays for insulin, proinsulin(s) and C-peptide. Ann Clin Biochem 1999;36:541-564.
17. Sapin R, Le Galudec V, Gasser F, Pinget M, Grucker D: Elecsys insulin assay: free insulin determination and the absence of cross-reactivity with insulin lispro. Clin Chem 2001;47:602-605.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
19. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M: Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998;47:1643-1649.
20. Shoji T, Emoto M, Nishizawa Y: HOMA index to assess insulin resistance in renal failure patients. Nephron 2001;89:348-349.
21. Kim KH, Zhao L, Moon Y, Kang C, Sul HS: Dominant inhibitory adipocyte-specific secretory factor (ADSF)/resistin enhances adipogenesis and improves insulin sensitivity. Proc Natl Acad Sci USA 2004;101:6780-6785.
22. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS: Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003;88:4848-4856.
23. Steppan CM, Lazar MA: Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002;13:18-23.
24. Diez JJ, Iglesias P, Fernandez-Reyes MJ, Aguilera A, Bajo MA, Alvarez-Fidalgo P, Codoceo R, Selgas R: Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf) 2005;62:242-249.
25. Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D: Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003;42:62-66.
26. Steppan CM, Lazar MA: The current biology of resistin. J Intern Med 2004;255:439-447.
27. Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW, Scherer PE, Rossetti L: Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004;114:232-239.
28. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA: Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 2004;53:1937-1941.
29. Collins AJ, Hanson G, Umen A, Kjellstrand C, Keshaviah P: Changing risk factor demographics in end-stage renal disease patients entering hemodialysis and the impact on long-term mortality. Am J Kidney Dis 1990;15:422-432.
30. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003;14:3270-3277.
31. Chudek J, Adamczak M, Karkoszka H, Budzinski G, Ignacy W, Funahashi T, Matsuzawa Y, Cierpka L, Kokot F, Wiecek A: Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003;35:2186-2189.
32. Marchlewska A, Stenvinkel P, Lindholm B, Danielsson A, Pecoits-Filho R, Lonnqvist F, Schalling M, Heimburger O, Nordfors L: Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int 2004;66:46-50.
33. Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, Catalano F, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y: Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl 2003;S98-S102.
34. Zoccali C, Mallamaci F, Tripepi G: Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney Int Suppl 2003;84:S65-S68.
35. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134-141.
36. Burrowes JD, Cockram DB, Dwyer JT, Larive B, Paranandi L, Bergen C, Poole D: Cross-sectional relationship between dietary protein and energy intake, nutritional status, functional status, and comorbidity in older versus younger hemodialysis patients. J Ren Nutr 2002;12:87-95.
37. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. Obes Res 1998;6(suppl 2):51S-209S.
38. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS: Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003;88:1730-1736.
39. Bertile F, Raclot T: Differences in mRNA expression of adipocyte-derived factors in response to fasting, refeeding and leptin. Biochim Biophys Acta 2004;1683:101-109.